sodium selenate profile

Sodium selenate (Na2SeO4) is an inorganic compound that is a white crystalline solid. It is a highly soluble salt that is typically synthesized through the reaction of selenium dioxide with sodium hydroxide. Sodium selenate is an important component of selenium supplements, as selenium is an essential trace element required for various biological functions, including antioxidant defense and thyroid hormone metabolism. Studies on sodium selenate explore its role in cancer prevention, its potential to protect against neurodegenerative diseases, and its effects on immune system function.'

sodium selenate : An inorganic sodium salt having selenate as the counterion. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	25960
CHEBI ID	77775
MeSH ID	M0077028
PubMed CID	9804450
CHEMBL ID	301160
SCHEMBL ID	11805323
MeSH ID	M0077028

Synonym
sodium selenate
13410-01-0
ai3-10625
selenic acid (h2seo4), disodium salt
sel-tox sso2 and ss-20
sodium selenium oxide (na2seo4)
natriumseleniat [german]
hsdb 6370
nsc 378348
caswell no. 791
ccris 1259
epa pesticide chemical code 072002
selenic acid, disodium salt
einecs 236-501-8
disodium selenate
chebi:77775 ,
sodium selenium oxide
5dqp25600a ,
natriumseleniat
selenic acid, sodium salt (1:2)
unii-5dqp25600a
sodium selenate [mart.]
sodium selenate [hsdb]
sodium selenate [who-dd]
selenium (as sodium selenate) [vandf]
sodium selenate [mi]
AKOS015914024
DTXSID5032076
sodium selenate, anhydrous
mfcd00003490
J-006483
Q419488
disodium;selenate
selenate de sodium
selenato de sodio
selenato di sodio
3-hydroxy-n-cyclobutylmethylmorphinan
(-)-3-hydroxy-n-cyclobutylmethylmorphinan s(+)-mandelate
butorphan
bdbm50135808
17-cyclobutylmethyl-(1r,9r,10r)-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-4-ol
CHEMBL301160 ,
SCHEMBL11805323
3-hydroxy-n-cyclobutylmethyl morphinan
unii-6ks5448qqj
6KS5448QQJ ,
mcl-101 free base
(1r,9r,10r)-17-(cyclobutylmethyl)-17-azatetracyclo(7.5.3.0(1,10).0(2,7))heptadeca-2(7),3,5-trien-4-ol
n-(cyclobutylmethyl)morphinan-3-ol
morphinan, n-(cyclobutylmethyl)-3-hydroxy-
(-)-butorphan
morphinan-3-ol, 17-(cyclobutylmethyl)-
morphinan-3-ol, 17-(cyclobutylmethyl)-, (-)-
4163-26-2

Excerpt	Reference	Relevance
" All of the selenazolidines were much less toxic to the cells than was sodium selenite (IC(50) approximately 17 microM) or the parent selenolamines, L- or D-selenocystine (IC(50) approximately 34 or 39 microM, respectively); OSCA was less toxic than MSCA."	( Characteristics of selenazolidine prodrugs of selenocysteine: toxicity and glutathione peroxidase induction in V79 cells. Cassidy, PB; Li, L; Roberts, JC; Short, MD; Xie, Y, 2003)	0.32

Item	Process	Frequency
Waters	core-ingredient	4
Beverages	core-ingredient	4
Meal replacements	core-ingredient	2
Dietary supplements	core-ingredient	1
en:flavored-waters	core-ingredient	1
Vitamin waters	core-ingredient	1
Sweetened beverages	core-ingredient	1
Energy drinks	core-ingredient	1
Meals	core-ingredient	1

Role	Description
EC 3.1.3.48 (protein-tyrosine-phosphatase) inhibitor	An EC 3.1.3.* (phosphoric monoester hydrolase) inhibitor which interferes with the activity of the enzyme protein tyrosine phosphatases (PTPs), EC 3.1.3.48, involved in the removal of phosphate groups from phosphorylated tyrosine residues on proteins.
anticonvulsant	A drug used to prevent seizures or reduce their severity.
fertilizer	A fertilizer is any substance that is added to soil or water to assist the growth of plants.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
inorganic sodium salt
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase	Astrosclera willeyana	Ki	880.0000	0.0320	1.5172	9.6000	AID647373
Carbonic anhydrase 1	Homo sapiens (human)	Ki	103,321.2500	0.0000	1.3726	10.0000	AID1161930; AID416958; AID552781; AID598726; AID647371; AID714401; AID730754; AID763569
Carbonic anhydrase 2	Homo sapiens (human)	Ki	112,000.0000	0.0000	0.7236	9.9200	AID1058395; AID1070020; AID1161931; AID1161950; AID1235241; AID1237475; AID1336557; AID1430526; AID1461934; AID416959; AID552782; AID598728; AID647372; AID714400; AID730373; AID730753; AID758952
Carbonic anhydrase 4	Homo sapiens (human)	Ki	138,000.0000	0.0002	1.9720	9.9200	AID416960
Mu-type opioid receptor	Rattus norvegicus (Norway rat)	Ki	112,000.0000	0.0000	0.3845	8.6000	AID1161931
Carbonic anhydrase 7	Homo sapiens (human)	Ki	215,000.0000	0.0002	1.3737	9.9000	AID416961
Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0025	1.1480	9.2000	AID1374899
Carbonic anhydrase 13	Mus musculus (house mouse)	Ki	484,000.0000	0.0002	1.3974	9.9000	AID416962
Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0130	0.7995	4.9000	AID1374900
Carbonic anhydrase	Pseudomonas aeruginosa PAO1	Ki	23,500.0000	0.0759	6.2690	9.0000	AID1237477
Alpha-2B adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0001	0.0000	0.9296	10.0000	AID440059
Alpha-2C adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0001	0.0000	0.9708	10.0000	AID440059
Alpha-2A adrenergic receptor	Rattus norvegicus (Norway rat)	Ki	0.0001	0.0000	0.9375	10.0000	AID440059
Mu-type opioid receptor	Homo sapiens (human)	IC50 (µMol)	0.0200	0.0001	0.8133	10.0000	AID259402; AID286314; AID290265; AID296062; AID440064; AID670121
Mu-type opioid receptor	Homo sapiens (human)	Ki	0.0002	0.0000	0.4197	10.0000	AID1054068; AID1274735; AID148328; AID151001; AID259394; AID286302; AID290256; AID296053; AID362196; AID440057; AID445095; AID465986; AID592435; AID596551; AID670110
Delta-type opioid receptor	Homo sapiens (human)	Ki	0.0056	0.0000	0.5978	9.9300	AID1054066; AID1274731; AID147944; AID148369; AID149778; AID259395; AID286304; AID290258; AID296055; AID362197; AID440058; AID445097; AID465988; AID596638; AID670113
Kappa-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0030	0.0000	0.2018	6.4240	AID147944; AID149121
Kappa-type opioid receptor	Homo sapiens (human)	Ki	0.0001	0.0000	0.3624	10.0000	AID1054067; AID1274742; AID148149; AID149978; AID259396; AID286303; AID290257; AID296054; AID362198; AID440059; AID445096; AID465987; AID592432; AID596552; AID670111
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	Ki	0.0002	0.0000	0.2786	9.0000	AID147903
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Alpha-1B adrenergic receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0013	0.0013	2.6129	25.7000	AID440066
Alpha-1D adrenergic receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0013	0.0013	3.3946	25.7000	AID440066
Mu-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.0016	0.0000	0.3263	9.4000	AID148326; AID259402; AID286312; AID290264; AID296061; AID440062; AID670119
Kappa-type opioid receptor	Homo sapiens (human)	EC50 (µMol)	0.0013	0.0000	0.2244	8.9900	AID149976; AID149994; AID259400; AID286308; AID290262; AID296058; AID440066; AID670123
Alpha-1A adrenergic receptor	Rattus norvegicus (Norway rat)	EC50 (µMol)	0.0013	0.0013	3.3946	25.7000	AID440066
Mu-type opioid receptor	Cavia porcellus (domestic guinea pig)	EC50 (µMol)	0.0013	0.0000	0.0493	0.9320	AID149994
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Carbonic anhydrase 12	Homo sapiens (human)	Kinact	138,000.0000	0.0030	0.6674	9.6000	AID465235
Carbonic anhydrase 9	Homo sapiens (human)	Kinact	183,000.0000	0.0050	0.3197	6.6700	AID465234
Carbonic anhydrase 14	Homo sapiens (human)	Kinact	49,600.0000	0.0002	1.4495	8.5900	AID465236
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
estrous cycle	Carbonic anhydrase 12	Homo sapiens (human)
chloride ion homeostasis	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 12	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 1	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 2	Homo sapiens (human)
angiotensin-activated signaling pathway	Carbonic anhydrase 2	Homo sapiens (human)
regulation of monoatomic anion transport	Carbonic anhydrase 2	Homo sapiens (human)
secretion	Carbonic anhydrase 2	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 2	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 2	Homo sapiens (human)
positive regulation of dipeptide transmembrane transport	Carbonic anhydrase 2	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 2	Homo sapiens (human)
carbon dioxide transport	Carbonic anhydrase 2	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 2	Homo sapiens (human)
bicarbonate transport	Carbonic anhydrase 4	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 4	Homo sapiens (human)
positive regulation of synaptic transmission, GABAergic	Carbonic anhydrase 7	Homo sapiens (human)
positive regulation of cellular pH reduction	Carbonic anhydrase 7	Homo sapiens (human)
neuron cellular homeostasis	Carbonic anhydrase 7	Homo sapiens (human)
regulation of chloride transport	Carbonic anhydrase 7	Homo sapiens (human)
regulation of intracellular pH	Carbonic anhydrase 7	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 7	Homo sapiens (human)
response to hypoxia	Carbonic anhydrase 9	Homo sapiens (human)
morphogenesis of an epithelium	Carbonic anhydrase 9	Homo sapiens (human)
response to xenobiotic stimulus	Carbonic anhydrase 9	Homo sapiens (human)
response to testosterone	Carbonic anhydrase 9	Homo sapiens (human)
secretion	Carbonic anhydrase 9	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 9	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to starvation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of DNA replication	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
synaptonemal complex assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
spermatid development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
long-term memory	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
fertilization	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
peptidyl-lysine dimethylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
regulation of protein modification process	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
organ growth	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
phenotypic switching	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of gene expression via chromosomal CpG island methylation	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to ethanol	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
behavioral response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
oocyte development	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
neuron fate specification	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
response to fungicide	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to cocaine	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
cellular response to xenobiotic stimulus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of autophagosome assembly	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
chromatin organization	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
DNA methylation-dependent heterochromatin formation	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
peptidyl-lysine monomethylation	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
peptidyl-lysine dimethylation	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
negative regulation of DNA-templated transcription	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
regulation of embryonic development	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
response to fungicide	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
positive regulation of cold-induced thermogenesis	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
one-carbon metabolic process	Carbonic anhydrase 14	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Mu-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
sensory perception	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of cell population proliferation	Mu-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
behavioral response to ethanol	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of neurogenesis	Mu-type opioid receptor	Homo sapiens (human)
negative regulation of Wnt protein secretion	Mu-type opioid receptor	Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascade	Mu-type opioid receptor	Homo sapiens (human)
calcium ion transmembrane transport	Mu-type opioid receptor	Homo sapiens (human)
cellular response to morphine	Mu-type opioid receptor	Homo sapiens (human)
regulation of cellular response to stress	Mu-type opioid receptor	Homo sapiens (human)
regulation of NMDA receptor activity	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Mu-type opioid receptor	Homo sapiens (human)
immune response	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger	Delta-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
adult locomotory behavior	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of gene expression	Delta-type opioid receptor	Homo sapiens (human)
negative regulation of protein-containing complex assembly	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of CREB transcription factor activity	Delta-type opioid receptor	Homo sapiens (human)
positive regulation of peptidyl-serine phosphorylation	Delta-type opioid receptor	Homo sapiens (human)
response to nicotine	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
eating behavior	Delta-type opioid receptor	Homo sapiens (human)
regulation of mitochondrial membrane potential	Delta-type opioid receptor	Homo sapiens (human)
regulation of calcium ion transport	Delta-type opioid receptor	Homo sapiens (human)
cellular response to growth factor stimulus	Delta-type opioid receptor	Homo sapiens (human)
cellular response to hypoxia	Delta-type opioid receptor	Homo sapiens (human)
cellular response to toxic substance	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Delta-type opioid receptor	Homo sapiens (human)
immune response	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
chemical synaptic transmission	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception	Kappa-type opioid receptor	Homo sapiens (human)
locomotory behavior	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of pain	Kappa-type opioid receptor	Homo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
response to insulin	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of dopamine secretion	Kappa-type opioid receptor	Homo sapiens (human)
negative regulation of luteinizing hormone secretion	Kappa-type opioid receptor	Homo sapiens (human)
response to nicotine	Kappa-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
maternal behavior	Kappa-type opioid receptor	Homo sapiens (human)
eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
response to estrogen	Kappa-type opioid receptor	Homo sapiens (human)
estrous cycle	Kappa-type opioid receptor	Homo sapiens (human)
response to ethanol	Kappa-type opioid receptor	Homo sapiens (human)
regulation of saliva secretion	Kappa-type opioid receptor	Homo sapiens (human)
behavioral response to cocaine	Kappa-type opioid receptor	Homo sapiens (human)
sensory perception of temperature stimulus	Kappa-type opioid receptor	Homo sapiens (human)
defense response to virus	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to lipopolysaccharide	Kappa-type opioid receptor	Homo sapiens (human)
cellular response to glucose stimulus	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of p38MAPK cascade	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of potassium ion transmembrane transport	Kappa-type opioid receptor	Homo sapiens (human)
response to acrylamide	Kappa-type opioid receptor	Homo sapiens (human)
positive regulation of eating behavior	Kappa-type opioid receptor	Homo sapiens (human)
conditioned place preference	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide signaling pathway	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
zinc ion binding	Carbonic anhydrase 12	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 12	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 1	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
protein binding	Carbonic anhydrase 1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 1	Homo sapiens (human)
hydro-lyase activity	Carbonic anhydrase 1	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 1	Homo sapiens (human)
arylesterase activity	Carbonic anhydrase 2	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 2	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 2	Homo sapiens (human)
cyanamide hydratase activity	Carbonic anhydrase 2	Homo sapiens (human)
protein binding	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 4	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 4	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 7	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 9	Homo sapiens (human)
protein binding	Carbonic anhydrase 9	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 9	Homo sapiens (human)
molecular function activator activity	Carbonic anhydrase 9	Homo sapiens (human)
RNA polymerase II transcription regulatory region sequence-specific DNA binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
transcription corepressor binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
p53 binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
zinc ion binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
protein-lysine N-methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
enzyme binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K27 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
C2H2 zinc finger domain binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K56 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
histone H3K9me2 methyltransferase activity	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
promoter-specific chromatin binding	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
transcription corepressor binding	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
p53 binding	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
protein binding	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
methyltransferase activity	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
zinc ion binding	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
protein-lysine N-methyltransferase activity	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
histone H3K9 methyltransferase activity	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
histone H3K27 methyltransferase activity	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
C2H2 zinc finger domain binding	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
histone H3K9me2 methyltransferase activity	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
zinc ion binding	Carbonic anhydrase 14	Homo sapiens (human)
carbonate dehydratase activity	Carbonic anhydrase 14	Homo sapiens (human)
G-protein alpha-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled receptor activity	Mu-type opioid receptor	Homo sapiens (human)
beta-endorphin receptor activity	Mu-type opioid receptor	Homo sapiens (human)
voltage-gated calcium channel activity	Mu-type opioid receptor	Homo sapiens (human)
protein binding	Mu-type opioid receptor	Homo sapiens (human)
morphine receptor activity	Mu-type opioid receptor	Homo sapiens (human)
G-protein beta-subunit binding	Mu-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Mu-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Delta-type opioid receptor	Homo sapiens (human)
protein binding	Delta-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled enkephalin receptor activity	Delta-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Delta-type opioid receptor	Homo sapiens (human)
G protein-coupled opioid receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
protein binding	Kappa-type opioid receptor	Homo sapiens (human)
receptor serine/threonine kinase binding	Kappa-type opioid receptor	Homo sapiens (human)
dynorphin receptor activity	Kappa-type opioid receptor	Homo sapiens (human)
neuropeptide binding	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
membrane	Carbonic anhydrase 12	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 12	Homo sapiens (human)
cytosol	Carbonic anhydrase 1	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 1	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
cytosol	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
myelin sheath	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 2	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 2	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 2	Homo sapiens (human)
apical part of cell	Carbonic anhydrase 2	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
rough endoplasmic reticulum	Carbonic anhydrase 4	Homo sapiens (human)
endoplasmic reticulum-Golgi intermediate compartment	Carbonic anhydrase 4	Homo sapiens (human)
Golgi apparatus	Carbonic anhydrase 4	Homo sapiens (human)
trans-Golgi network	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
external side of plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cell surface	Carbonic anhydrase 4	Homo sapiens (human)
membrane	Carbonic anhydrase 4	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
transport vesicle membrane	Carbonic anhydrase 4	Homo sapiens (human)
secretory granule membrane	Carbonic anhydrase 4	Homo sapiens (human)
brush border membrane	Carbonic anhydrase 4	Homo sapiens (human)
perinuclear region of cytoplasm	Carbonic anhydrase 4	Homo sapiens (human)
extracellular exosome	Carbonic anhydrase 4	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 4	Homo sapiens (human)
cytosol	Carbonic anhydrase 7	Homo sapiens (human)
cytoplasm	Carbonic anhydrase 7	Homo sapiens (human)
nucleolus	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
membrane	Carbonic anhydrase 9	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
microvillus membrane	Carbonic anhydrase 9	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 9	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nuclear speck	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT2	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
nucleoplasm	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
nuclear body	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
chromatin	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
nucleus	Histone-lysine N-methyltransferase EHMT1	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
membrane	Carbonic anhydrase 14	Homo sapiens (human)
basolateral plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
apical plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
plasma membrane	Carbonic anhydrase 14	Homo sapiens (human)
endosome	Mu-type opioid receptor	Homo sapiens (human)
endoplasmic reticulum	Mu-type opioid receptor	Homo sapiens (human)
Golgi apparatus	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
axon	Mu-type opioid receptor	Homo sapiens (human)
dendrite	Mu-type opioid receptor	Homo sapiens (human)
perikaryon	Mu-type opioid receptor	Homo sapiens (human)
synapse	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Mu-type opioid receptor	Homo sapiens (human)
neuron projection	Mu-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Delta-type opioid receptor	Homo sapiens (human)
dendrite membrane	Delta-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Delta-type opioid receptor	Homo sapiens (human)
axon terminus	Delta-type opioid receptor	Homo sapiens (human)
spine apparatus	Delta-type opioid receptor	Homo sapiens (human)
postsynaptic density membrane	Delta-type opioid receptor	Homo sapiens (human)
neuronal dense core vesicle	Delta-type opioid receptor	Homo sapiens (human)
plasma membrane	Delta-type opioid receptor	Homo sapiens (human)
neuron projection	Delta-type opioid receptor	Homo sapiens (human)
nucleoplasm	Kappa-type opioid receptor	Homo sapiens (human)
mitochondrion	Kappa-type opioid receptor	Homo sapiens (human)
cytosol	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
membrane	Kappa-type opioid receptor	Homo sapiens (human)
sarcoplasmic reticulum	Kappa-type opioid receptor	Homo sapiens (human)
T-tubule	Kappa-type opioid receptor	Homo sapiens (human)
dendrite	Kappa-type opioid receptor	Homo sapiens (human)
synaptic vesicle membrane	Kappa-type opioid receptor	Homo sapiens (human)
presynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
perikaryon	Kappa-type opioid receptor	Homo sapiens (human)
axon terminus	Kappa-type opioid receptor	Homo sapiens (human)
postsynaptic membrane	Kappa-type opioid receptor	Homo sapiens (human)
plasma membrane	Kappa-type opioid receptor	Homo sapiens (human)
neuron projection	Kappa-type opioid receptor	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (208)

Assay ID	Title	Year	Journal	Article
AID1312218	Inhibition of Plasmodium falciparum full length recombinant His-fused Eta-carbonic anhydrase domain preincubated for 15 mins by stopped-flow CO2 hydrase assay	2016	Bioorganic & medicinal chemistry, 09-15, Volume: 24, Issue:18	Anion inhibition profiles of the complete domain of the η-carbonic anhydrase from Plasmodium falciparum.
AID598728	Inhibition of recombinant human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay at pH 8.3	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium.
AID1070021	Inhibition of Legionella pneumophila carbonic anhydrase 2 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Anion inhibition studies of two new β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1237475	Inhibition of human carbonic anhydrase-2 by CO2 hydration reaction based colorimetric stopped-flow method	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Structure and inhibition studies of a type II beta-carbonic anhydrase psCA3 from Pseudomonas aeruginosa.
AID1374897	Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1461938	Inhibition of recombinant His6-tagged Francisella tularensis beta-CA (227 residues) expressed in Escherichia coli BL21(DE3) incubated for 15 mins by stopped-flow CO2 hydration assay
AID763569	Inhibition of human carbonic anhydrase-1 at 20 degC preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
AID1461935	Inhibition of Burkholderia pseudomallei beta-CA incubated for 15 mins by stopped-flow CO2 hydration assay
AID216730	Cytotoxicity activity against V79 cells	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Characteristics of selenazolidine prodrugs of selenocysteine: toxicity and glutathione peroxidase induction in V79 cells.
AID763567	Inhibition of Brucella suis beta carbonic anhydrase-1 at 20 degC by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
AID1235244	Inhibition of Nostoc commune CA after 15 mins by stopped-flow/Co2 hydration assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID647373	Inhibition of Astrosclera willeyana recombinant GST-tagged astrosclerin 3 expressed in Escherichia coli BL21-DE3-RIPL cells preincubated for 15 mins measured for 10 to 100 secs by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Anion inhibition studies of an α-carbonic anhydrase from the living fossil Astrosclera willeyana.
AID758950	Inhibition of Methanosarcina thermophila recombinant gamma-CA by CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14	A highly catalytically active γ-carbonic anhydrase from the pathogenic anaerobe Porphyromonas gingivalis and its inhibition profile with anions and small molecules.
AID1336558	Inhibition of Methanosarcina thermophila recombinant carbonic anhydrase gamma assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID763566	Inhibition of Brucella suis beta carbonic anhydrase-2 at 20 degC by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
AID323921	Enhancement of HCV RNA replication in OR6 cells after 72 hrs by luciferase reporter assay	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture.
AID1058395	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Anion inhibition studies of a β-carbonic anhydrase from Clostridium perfringens.
AID763565	Inhibition of recombinant Trypanosoma cruzi CL Brener alpha carbonic anhydrase expressed in baculovirus infected SF9 cells at 20 degC preincubated for 15 mins by stopped-flow CO2 hydrase assay	2013	Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15	Anion inhibition studies of the α-carbonic anhydrase from the protozoan pathogen Trypanosoma cruzi, the causative agent of Chagas disease.
AID416958	Inhibition of human recombinant carbonic anhydrase 1-catalyzed CO2 hydration by stopped flow assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions.
AID730752	Inhibition of Helicobacter pylori alpha carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Anion inhibition studies of the α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID714401	Inhibition of human cytosolic carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense.
AID416960	Inhibition of human recombinant carbonic anhydrase 4-catalyzed CO2 hydration by stopped flow assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions.
AID1336560	Inhibition of Nostoc commune recombinant carbonic anhydrase gamma assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID1235242	Inhibition of archaeon Methanosarcina thermophila gamma-CA after 15 mins by stopped-flow/Co2 hydration assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID1161930	Inhibition of human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases.
AID416962	Inhibition of mouse recombinant carbonic anhydrase 13-catalyzed CO2 hydration by stopped flow assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions.
AID714400	Inhibition of human cytosolic carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense.
AID1070020	Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Anion inhibition studies of two new β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID75283	Glutathione peroxidase activity in V79 cells at 100 uM expressed as fold induction of GPx activity to control value	2003	Journal of medicinal chemistry, Jul-17, Volume: 46, Issue:15	Characteristics of selenazolidine prodrugs of selenocysteine: toxicity and glutathione peroxidase induction in V79 cells.
AID1430528	Inhibition of Burkholderia pseudomallei recombinant His-tagged carbonic anhydrase beta (256 residues) expressed in Escherichia coli BL21 (DE3) incubated for 15 mins prior to testing by stopped flow CO2 hydration method
AID1161951	Inhibition of Porphyromonas gingivalis gamma-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Anion inhibition study of the β-class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis.
AID758948	Inhibition of Porphyromonas gingivalis recombinant CA by CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14	A highly catalytically active γ-carbonic anhydrase from the pathogenic anaerobe Porphyromonas gingivalis and its inhibition profile with anions and small molecules.
AID416959	Inhibition of human recombinant carbonic anhydrase 2-catalyzed CO2 hydration by stopped flow assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions.
AID1430526	Inhibition of recombinant human carbonic anhydrase 2 assessed as inhibition of CO2 hydration incubated for 15 mins prior to testing by stopped flow CO2 hydration method
AID552785	Inhibition of Streptococcus pneumoniae beta-carbonic anhydrase after 15 mins by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?
AID1430527	Inhibition of Burkholderia pseudomallei recombinant carbonic anhydrase gamma incubated for 15 mins prior to testing by stopped flow CO2 hydration method
AID416961	Inhibition of human recombinant carbonic anhydrase 7-catalyzed CO2 hydration by stopped flow assay	2009	Bioorganic & medicinal chemistry letters, Apr-01, Volume: 19, Issue:7	Carbonic anhydrase inhibitors. Inhibition of cytosolic isoforms I, II, III, VII and XIII with less investigated inorganic anions.
AID1235245	Inhibition of Pseudoalteromonas haloplanktis gamma-CA after 15 mins by stopped-flow/Co2 hydration assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID677270	Inhibition of Sulfurihydrogenibium yellowstonense YO3AOP1 alpha-carbonic anhydrase-catalyzed CO2 hydration reaction preincubated for 15 mins by stopped flow CO2 hydrase assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Anion inhibition studies of an α-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1.
AID465236	Inhibition of human recombinant CA14 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate.
AID1237477	Inhibition of Pseudomonas aeruginosa PAO1 type-2 beta-carbonic anhydrase psCA3 expressed in Escherichia coli Tuner BL21 (DE3) cells pre-incubated for 15 mins at pH 8.3 and 293K by CO2 hydration reaction based colorimetric stopped-flow method	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Structure and inhibition studies of a type II beta-carbonic anhydrase psCA3 from Pseudomonas aeruginosa.
AID730753	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Anion inhibition studies of the α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID677271	Inhibition of Helicobacter pylori alpha-carbonic anhydrase-catalyzed CO2 hydration reaction preincubated for 15 mins by stopped flow CO2 hydrase assay	2012	Bioorganic & medicinal chemistry letters, Sep-01, Volume: 22, Issue:17	Anion inhibition studies of an α-carbonic anhydrase from the thermophilic bacterium Sulfurihydrogenibium yellowstonense YO3AOP1.
AID1235243	Inhibition of Porphyromonas gingivalis CA after 15 mins by stopped-flow/Co2 hydration assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID730754	Inhibition of human carbonic anhydrase 1 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Anion inhibition studies of the α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID730372	Inhibition of Flaveria bidentis beta-carbonic anhydrase-1 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Kinetic and anion inhibition studies of a β-carbonic anhydrase (FbiCA 1) from the C4 plant Flaveria bidentis.
AID1461934	Inhibition of human CA2 incubated for 15 mins by stopped-flow CO2 hydration assay
AID598731	Inhibition of Salmonella Typhimurium carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay at pH 8.3	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium.
AID465234	Inhibition of human recombinant CA9 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate.
AID758952	Inhibition of human recombinant CA2 by CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 23, Issue:14	A highly catalytically active γ-carbonic anhydrase from the pathogenic anaerobe Porphyromonas gingivalis and its inhibition profile with anions and small molecules.
AID1374901	Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID598726	Inhibition of recombinant human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay at pH 8.3	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium.
AID1058389	Inhibition of Clostridium perfringens carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Dec-15, Volume: 23, Issue:24	Anion inhibition studies of a β-carbonic anhydrase from Clostridium perfringens.
AID1269931	Inhibition of Colwellia psychrerythraea gamma carbonic anhydrase expressed in Escherichia coli incubated for 15 mins prior to testing by stopped flow CO2 hydration method	2016	Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4	Cloning, characterization and anion inhibition studies of a γ-carbonic anhydrase from the Antarctic bacterium Colwellia psychrerythraea.
AID1161950	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Anion inhibition study of the β-class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis.
AID598732	Inhibition of Salmonella Typhimurium carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay at pH 8.3	2011	Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12	Inhibition studies with anions and small molecules of two novel β-carbonic anhydrases from the bacterial pathogen Salmonella enterica serovar Typhimurium.
AID1374899	Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374895	Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 10 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM additi	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374900	Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addition measur	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1235241	Inhibition of human CA2 after 15 mins by stopped-flow/Co2 hydration assay	2015	Bioorganic & medicinal chemistry, Aug-01, Volume: 23, Issue:15	Cloning, characterization and anion inhibition studies of a new γ-carbonic anhydrase from the Antarctic bacterium Pseudoalteromonas haloplanktis.
AID730751	Inhibition of Vibrio cholerae alpha carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Anion inhibition studies of the α-carbonic anhydrase from the pathogenic bacterium Vibrio cholerae.
AID1161932	Inhibition of recombinant Plasmodium falciparum eta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases.
AID714403	Inhibition of Sulfurihydrogenibium azorense alpha-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 22, Issue:23	Anion inhibition studies of the fastest carbonic anhydrase (CA) known, the extremo-CA from the bacterium Sulfurihydrogenibium azorense.
AID1161931	Inhibition of human carbonic anhydrase 2 preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Discovery of a new family of carbonic anhydrases in the malaria pathogen Plasmodium falciparum--the η-carbonic anhydrases.
AID1336561	Inhibition of Pseudoalteromonas haloplanktis recombinant carbonic anhydrase gamma assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID730373	Inhibition of human cytosolic carbonic anhydrase-2 preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Kinetic and anion inhibition studies of a β-carbonic anhydrase (FbiCA 1) from the C4 plant Flaveria bidentis.
AID647372	Inhibition of human recombinant carbonic anhydrase 2 by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Anion inhibition studies of an α-carbonic anhydrase from the living fossil Astrosclera willeyana.
AID730368	Inhibition of Helicobacter pylori beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration assay	2013	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 23, Issue:6	Kinetic and anion inhibition studies of a β-carbonic anhydrase (FbiCA 1) from the C4 plant Flaveria bidentis.
AID1161952	Inhibition of Porphyromonas gingivalis beta-carbonic anhydrase preincubated for 15 mins by stopped flow CO2 hydration method	2014	Bioorganic & medicinal chemistry letters, Sep-15, Volume: 24, Issue:18	Anion inhibition study of the β-class carbonic anhydrase (PgiCAb) from the oral pathogen Porphyromonas gingivalis.
AID552781	Inhibition of human carbonic anhydrase 1 after 15 mins by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?
AID1070022	Inhibition of Legionella pneumophila carbonic anhydrase 1 preincubated for 15 mins by stopped-flow CO2 hydrase assay	2014	Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4	Anion inhibition studies of two new β-carbonic anhydrases from the bacterial pathogen Legionella pneumophila.
AID1336557	Inhibition of human recombinant carbonic anhydrase 2 assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID552782	Inhibition of human carbonic anhydrase 2 after 15 mins by stopped flow CO2 hydration assay	2011	Bioorganic & medicinal chemistry, Jan-01, Volume: 19, Issue:1	Inhibition of the β-carbonic anhydrase from Streptococcus pneumoniae by inorganic anions and small molecules: Toward innovative drug design of antiinfectives?
AID1374902	Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS assessed as zinc ions ejection from Cys4-Zn finger at 100 uM by FluoZin-3 based fluorescence assay	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID465235	Inhibition of human recombinant CA12 by stopped flow CO2 hydration assay	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Carbonic anhydrase inhibitors. Inhibition of transmembrane isoforms IX, XII, and XIV with less investigated anions including trithiocarbonate and dithiocarbamate.
AID1336562	Inhibition of Burkholderia pseudomallei recombinant His-tagged carbonic anhydrase gamma expressed in Escherichia coli BL21 (DE3) assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID1374896	Inhibition of wild type recombinant human histone lysine methyltransferase G9a (913 to 1193 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID1374898	Inhibition of wild type recombinant human histone lysine methyltransferase GLP (951 to 1235 residues) expressed in Escherichia coli Rosetta BL21 DE3 PlysS at 100 uM using ARTKQTARKSTGGKA as substrate preincubated for 5 mins followed by substrate/SAM addit	2018	Bioorganic & medicinal chemistry letters, 04-15, Volume: 28, Issue:7	Inhibition of histone lysine methyltransferases G9a and GLP by ejection of structural Zn(II).
AID647371	Inhibition of human recombinant carbonic anhydrase 1 by stopped flow CO2 hydration assay	2012	Bioorganic & medicinal chemistry letters, Feb-01, Volume: 22, Issue:3	Anion inhibition studies of an α-carbonic anhydrase from the living fossil Astrosclera willeyana.
AID1336559	Inhibition of Porphyromonas gingivalis recombinant carbonic anhydrase gamma assessed as inhibition of CO2 hydration preincubated for 15 mins by Lineweaver-burk plot method
AID229399	Relative affinity for mu and kappa opioid receptors	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID259396	Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID235163	Selectivity ratio expressed as Ki of delta opioid receptor to that of kappa opioid receptor.	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
AID596551	Displacement of [3H]DAMGO from human mu-opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID362196	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membrane	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID1054056	Reduction of reward potentiation effect of cocaine in ip dosed Sprague-Dawley rat assessed as blockade of cocaine-madiated reduction of intracranial self-stimulation threshold administered for 15 mins prior to cocaine challenge measured 15 mins post dose	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID259402	Activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID440062	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID670117	Selectivity index, ratio of inhibition of human mu opioid receptor to inhibition of human kappa opioid receptor	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID148034	Binding affinity towards Opioid receptor mu 1 by displacing the radioligand [3H]DAMGO from guinea pig brain membrane	2000	Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
AID229388	Relative affinity for delta and kappa opioid receptors	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID286312	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID1054067	Displacement of [3H]-U69593 from human kappa opioid receptor transfected in CHO cells after 60 mins	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID1054066	Displacement of [3H]-naltrindole from human delta opioid receptor transfected in CHO cells after 3 hrs	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID445097	Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO cells	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
AID296060	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding relative to basal level after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID362201	Selectivity ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID592435	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Aminothiazolomorphinans with mixed κ and μ opioid activity.
AID149977	Binding ability against kappa opioid receptor by stimulating the [35S]GTP-gamma-S, radioligand in Chinese hamster ovary membranes	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID290265	Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as DAMGO-stimulated [35S]GTP-gamma-S binding	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID286305	Ratio of Ki for human opioid kappa receptor to Ki for human opioid gamma receptor	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID286306	Ratio of Ki for human opioid kappa receptor to Ki for human opioid delta receptor	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID149121	Binding affinity against opioid receptor kappa 1 using [3H]-U-69,593 as radioligand in guinea pig brain membranes.	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
AID286307	Agonist activity at human opioid kappa receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID670120	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting relative to control	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID286311	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID296061	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID148369	Inhibitory activity against Opioid receptor delta 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]naltrindole radioligand	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID445098	Selectivity ratio of Ki for human kappa opioid receptor to Ki for human mu opioid receptor	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
AID362200	Selectivity ratio of Ki for human mu opioid receptor to Ki for human delta opioid receptor	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID259395	Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO cells	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID235164	Selectivity ratio expressed as Ki of delta opioid receptor to that of mu opioid receptor.	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
AID670113	Displacement of [3H]-naltrindole from human delta opioid receptor expressed in CHO cells after 3 hrs by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID286304	Displacement of [3H]naltrindole from human opioid delta receptor expressed in CHO cells	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID1274731	Binding affinity at delta opioid receptor (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Multitarget opioid ligands in pain relief: New players in an old game.
AID290264	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID259401	Functional activity at human mu opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID362199	Selectivity ratio of Ki for human kappa opioid receptor to Ki for human delta opioid receptor	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID290260	Selectivity for kappa opioid receptor over delta opioid receptor	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID149270	Binding affinity towards Opioid receptor kappa 1 by displacing the radioligand [3H]U-69593 from guinea pig brain membrane	2000	Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
AID440061	Selectivity ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID286302	Displacement of [3H]DAMGO from human opioid gamma receptor expressed in CHO cells	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID235329	Selectivity ratio of kappa opioid receptor to that of delta opioid receptor in guinea pig brain membranes	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
AID670110	Displacement of [3H]-DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID670118	Selectivity index, ratio of inhibition of human delta opioid receptor to inhibition of human kappa opioid receptor	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID465988	Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO cell membranes after 3 hrs by scintillation counting	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
AID440064	Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-stimulated [35S]GTPgammaS binding	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID149904	Binding affinity towards Opioid receptor delta 1 in guinea pig brain membranes using [3H]naltrindole as radioligand	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
AID296058	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID290256	Displacement of [3H]DAMGO from human mu opioid receptors expressed in CHO cell membrane	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID223604	Selectivity kappa/mu	2000	Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
AID286314	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as inhibition of DAGO-stimulated [35S]GTPgammaS binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID596650	Selectivity ratio of Ki for human kappa opioid receptor over Ki for human delta opioid receptor	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID148327	Binding ability against Opioid receptor mu 1 by stimulating the [35S]GTP-gamma-S radioligand in Chinese hamster ovary membranes	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID290263	Antagonist activity against [35S]GTP-gamma-S binding from human kappa opioid receptors expressed in CHO cell membrane	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID445095	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
AID440068	Antagonist activity at human kappa opioid receptor expressed in CHO cells assessed as inhibition of U50488-stimulated [35S]GTPgammaS binding	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID596649	Selectivity ratio of Ki for human kappa opioid receptor over Ki for human mu opioid receptor	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID445099	Selectivity ratio of Ki for human delta opioid receptor to Ki for human mu opioid receptor	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
AID233831	Selective inhibitory activity was determined against kappa & mu opioid receptor in chinese Hamster Ovary (CHO) cell membranes	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID149902	Binding affinity towards Opioid receptor delta 1 by displacing the radioligand [3H]naltrindole from guinea pig brain membrane	2000	Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
AID147903	Binding affinity against opioid receptor mu 1 using [3H]DAMGO as radioligand in guinea pig brain membranes.	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
AID286303	Displacement of [3H]U-69593 from human opioid kappa receptor expressed in CHO cells	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID259398	Selectivity for human kappa opioid receptor over delta opioid receptor	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID149272	Binding affinity towards Opioid receptor kappa 1 in guinea pig brain membranes using [3H]U-69593 as radioligand	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
AID440060	Selectivity ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID286308	Agonist activity at human opioid kappa receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID465990	Selectivity ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
AID290258	Displacement of [3H]naltrindole from human delta opioid receptors expressed in CHO cell membrane	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID148326	Agonistic activity against Opioid receptor mu 1 in Chinese hamster ovary membranes	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID149976	Agonistic activity against kappa opioid receptor in Chinese hamster ovary membranes	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID235330	Selectivity ratio of kappa opioid receptor to that of mu opioid receptor in guinea pig brain membranes	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
AID440063	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTPgammaS binding relatiev to DAMGO	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID148158	Maximal percent inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes; Not Tested	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID1054059	Toxicity in Sprague-Dawley rat assessed as suppression of intracranial self-stimulation reward function at 0.25 to 2 mg/kg, ip measured for 1 hr	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID670123	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID296053	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO membrane	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID290262	Agonist activity at huma kappa opioid receptor expressed in CHO cells assessed as U50488-stimulated of [35S]GTP-gamma-S binding	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID296062	Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [35S]GTPgammaS binding after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID1054064	Selectivity ratio of Ki for human delta opioid receptor to Ki for human kappa opioid receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID296057	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTP-gamma-S binding relative to basal level after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID259397	Selectivity for human kappa opioid receptor over mu opioid receptor	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID362197	Displacement of [3H]Naltindole from human delta opioid receptor expressed in CHO cell membrane	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID296055	Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO membrane	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID465989	Selectivity ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
AID139099	Analgesic Potency was tested against mice	1990	Journal of medicinal chemistry, Oct, Volume: 33, Issue:10	A Free-Wilson/Fujita-Ban analysis and prediction of the analgesic potency of some 3-hydroxy- and 3-methoxy-N-alkylmorphinan-6-one opioids.
AID440059	Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID148036	Binding affinity towards Opioid receptor mu 1 in guinea pig brain membranes using [3H]DAMGO as radioligand	2001	Bioorganic & medicinal chemistry letters, Oct-22, Volume: 11, Issue:20	Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
AID259400	Activity at human kappa opioid receptor expressed in CHO cells by [35S]GTP-gamma-S binding assay	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID149994	Inhibitory activity in stimulating [35S]-GTP-gamma S binding mediated by the Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID670122	Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting relative to control	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID149978	Inhibition of [3H]U-69593 binding to Opioid receptor kappa 1 of Chinese hamster ovary membrane	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID465987	Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
AID596552	Displacement of [3H]U69563 from human kappa-opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID670111	Displacement of [3H]-U69,593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID286313	Agonist activity at human opioid gamma receptor expressed in CHO cells assessed as maximal inhibition of DAGO-stimulated [35S]GTP-gamma-S binding	2007	Journal of medicinal chemistry, May-03, Volume: 50, Issue:9	Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
AID465986	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cell membranes after 60 mins by scintillation counting	2010	Bioorganic & medicinal chemistry letters, Mar-01, Volume: 20, Issue:5	Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors.
AID670124	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting relative to control	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID440058	Displacement of [3H]naltrindole from human delta opioid receptor expressed in CHO cells after 3 hrs by liquid scintillation counting	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID445096	Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells	2010	Journal of medicinal chemistry, Jan-14, Volume: 53, Issue:1	Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors.
AID1274735	Binding affinity at mu opioid receptor (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Multitarget opioid ligands in pain relief: New players in an old game.
AID290261	Agonist activity at human opioid kappa receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTP-gamma-S binding relative to control	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID440066	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as stimulation of [35S]GTPgammaS binding	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID1054065	Selectivity ratio of Ki for human mu opioid receptor to Ki for human kappa opioid receptor	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID296059	Antagonist activity at human kappa opioid receptor expressed in CHO cells assessed as inhibition of U69,593-induced stimulation of [35S]GTP-gamma-S binding after 60 mins	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID296054	Displacement of [3H]U69,593 from human kappa opioid receptor expressed in CHO membrane	2007	Bioorganic & medicinal chemistry, Jun-15, Volume: 15, Issue:12	In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
AID1054068	Displacement of [3H]-DAMGO from human mu opioid receptor transfected in CHO cells after 60 mins	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID147852	Percent maximal stimulation in [35S]-GTP-gamma S binding assay mediated by the Opioid receptor kappa 1 in chinese Hamster Ovary (CHO)membranes	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID149778	Binding affinity against opioid receptor delta 1 using [3H]naltrindole as radioligand in guinea pig brain membranes.	2004	Journal of medicinal chemistry, Jan-01, Volume: 47, Issue:1	10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
AID670121	Antagonist activity at human mu opioid receptor expressed in CHO cells assessed as inhibition of DAMGO-induced [33S]GTPgammaS binding after 60 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID148149	Inhibitory activity against Opioid receptor kappa 1 in chinese Hamster Ovary (CHO) cell membranes was determined using [3H]U-69593 radioligand	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID147944	Inhibition of [3H]naltrindole binding to opioid receptor delta 1 of Chinese hamster ovary membrane	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID223602	Selectivity kappa/delta	2000	Journal of medicinal chemistry, Jan-13, Volume: 43, Issue:1	Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
AID1274742	Binding affinity to kappa opioid receptor (unknown origin)	2016	European journal of medicinal chemistry, Jan-27, Volume: 108	Multitarget opioid ligands in pain relief: New players in an old game.
AID592432	Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cells after 60 mins by scintillation counting	2011	Journal of medicinal chemistry, Mar-24, Volume: 54, Issue:6	Aminothiazolomorphinans with mixed κ and μ opioid activity.
AID290257	Displacement of [3H]U-69593 from human kappa opioid receptors expressed in CHO cell membrane	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
AID148328	Inhibition of [3H]-DAMGO binding to Opioid receptor mu 1 of Chinese hamster ovary membrane	2004	Journal of medicinal chemistry, Apr-08, Volume: 47, Issue:8	2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
AID440057	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells after 60 mins by liquid scintillation counting	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID1054057	Toxicity in Sprague-Dawley rat assessed as suppression of intracranial self-stimulation reward function at 4 mg/kg, ip measured over 15 to 60 mins	2013	Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21	Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
AID440067	Agonist activity at human kappa opioid receptor expressed in CHO cells assessed as maximal stimulation of [35S]GTPgammaS binding relatiev to U50488	2009	Journal of medicinal chemistry, Dec-10, Volume: 52, Issue:23	Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands.
AID233830	Selective inhibitory activity was determined against kappa & delta opioid receptor in chinese Hamster Ovary (CHO) cell membranes	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID596638	Displacement of [3H]naltrindole from human delta-opioid receptor expressed in CHO cells after 3 hrs by scintillation counting	2011	Bioorganic & medicinal chemistry, May-01, Volume: 19, Issue:9	Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
AID259394	Displacement of [3H]DAMGO from human mu opioid receptor expressed in CHO cells	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID670119	Agonist activity at human mu opioid receptor expressed in CHO cells assessed as stimulation of [33S]GTPgammaS binding after 60 mins by scintillation counting	2012	Journal of medicinal chemistry, Apr-26, Volume: 55, Issue:8	Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
AID259399	Functional activity at human kappa opioid receptor expressed CHO cells by [35S]GTPgammaS binding assay	2006	Journal of medicinal chemistry, Jan-12, Volume: 49, Issue:1	Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
AID362198	Displacement of [3H]U69593 from human kappa opioid receptor expressed in CHO cell membrane	2008	Bioorganic & medicinal chemistry letters, Aug-15, Volume: 18, Issue:16	Synthesis and pharmacological evaluation of hydrophobic esters and ethers of butorphanol at opioid receptors.
AID151001	Inhibitory activity against Opioid receptor mu 1 in chinese Hamster Ovary (CHO) cells membranes was determined using [3H]-DAMGO radioligand	2003	Journal of medicinal chemistry, Nov-20, Volume: 46, Issue:24	Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
AID290259	Selectivity for kappa opioid receptor over mu opioid receptor expressed in CHO cells	2007	Bioorganic & medicinal chemistry letters, Mar-15, Volume: 17, Issue:6	High-affinity carbamate analogues of morphinan at opioid receptors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	1 (2.22)	18.2507
2000's	15 (33.33)	29.6817
2010's	29 (64.44)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Trials	0 (0.00%)	5.53%
Reviews	0 (0.00%)	6.00%
Reviews	1 (5.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Observational	0 (0.00%)	0.25%
Other	25 (100.00%)	84.16%
Other	19 (95.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
dimethyl sulfoxide Dimethyl Sulfoxide: A highly polar organic liquid, that is used widely as a chemical solvent. Because of its ability to penetrate biological membranes, it is used as a vehicle for topical application of pharmaceuticals. It is also used to protect tissue during CRYOPRESERVATION. Dimethyl sulfoxide shows a range of pharmacological activity including analgesia and anti-inflammation.. dimethyl sulfoxide : A 2-carbon sulfoxide in which the sulfur atom has two methyl substituents.	2.17	1	sulfoxide; volatile organic compound	alkylating agent; antidote; Escherichia coli metabolite; geroprotector; MRI contrast agent; non-narcotic analgesic; polar aprotic solvent; radical scavenger
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.17	15	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
disulfiram [no description available]	2.17	1	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
ebselen ebselen : A benzoselenazole that is 1,2-benzoselenazol-3-one carrying an additional phenyl substituent at position 2. Acts as a mimic of glutathione peroxidase.	2.17	1	benzoselenazole	anti-inflammatory drug; antibacterial agent; anticoronaviral agent; antifungal agent; antineoplastic agent; antioxidant; apoptosis inducer; EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.3.1.8 [acyl-CoA dehydrogenase (NADP(+))] inhibitor; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.3.25 (inositol-phosphate phosphatase) inhibitor; EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor; EC 3.5.4.1 (cytosine deaminase) inhibitor; EC 5.1.3.2 (UDP-glucose 4-epimerase) inhibitor; enzyme mimic; ferroptosis inhibitor; genotoxin; hepatoprotective agent; neuroprotective agent; radical scavenger
sodium fluoride [no description available]	4.28	17	fluoride salt	mutagen
sodium iodide Sodium Iodide: A compound forming white, odorless deliquescent crystals and used as iodine supplement, expectorant or in its radioactive (I-131) form as an diagnostic aid, particularly for thyroid function tests.. sodium iodide : A metal iodide salt with a Na(+) counterion.	4.28	17	inorganic sodium salt; iodide salt
thiram Thiram: A dithiocarbamate chemical, used commercially in the rubber processing industry and as a fungicide. In vivo studies indicate that it inactivates the enzyme GLUTATHIONE REDUCTASE. It has mutagenic activity and may induce chromosomal aberrations.. thiram : An organic disulfide that results from the formal oxidative dimerisation of N,N-dimethyldithiocarbamic acid. It is widely used as a fungicidal seed treatment.	2.17	1	organic disulfide	antibacterial drug; antifungal agrochemical; antiseptic drug
1,4-phenylenebis(methylene)selenocyanate 1,4-phenylenebis(methylene)selenocyanate: structure given in first source; inhibits DMBA-induced carcinogenesis by inhibiting DMBA-DNA adduct formation	2.01	1
cystamine dihydrochloride [no description available]	2.17	1
sulfamic acid sulfamic acid: standard in alkalimetry; RN given refers to parent cpd; structure. sulfamic acid : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to hydroxy and amino groups and by double bonds to two oxygen atoms.	4.17	15	sulfamic acids
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	2.17	1	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
9,10-anthraquinone 9,10-anthraquinone : An anthraquinone that is anthracene in which positions 9 and 10 have been oxidised to carbonyls.	2.17	1	anthraquinone
benzenearsonic acid benzenearsonic acid: RN given refers to parent cpd; structure	4.23	16	arsonic acids; organoarsonic acid
1,4-naphthoquinone naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.	2.17	1	1,4-naphthoquinones
sodium cyanide Sodium Cyanide: A highly poisonous compound that is an inhibitor of many metabolic processes and is used as a test reagent for the function of chemoreceptors. It is also used in many industrial processes.. sodium cyanide : A cyanide salt containing equal numbers of sodium cations and cyanide anions.	4.28	17	cyanide salt; one-carbon compound; sodium salt	EC 1.15.1.1 (superoxide dismutase) inhibitor
ninhydrin Ninhydrin: 2,2-Dihydroxy-1H-indene-1,3-(2H)-dione. Reagent toxic to skin and mucus membranes. It is used in chemical assay for peptide bonds, i.e., protein determinations and has radiosensitizing properties.. ninhydrin : A member of the class of indanones that is indane-1,3-dione bearing two additional hydroxy substituents at position 2.	2.17	1	aromatic ketone; beta-diketone; indanones; ketone hydrate	colour indicator; human metabolite
sodium carbonate sodium carbonate: used topically for dermatitides, mouthwash, vaginal douche; veterinary use as emergency emetic; RN given refers to carbonic acid, di-Na salt; structure	4.23	16	carbonate salt; organic sodium salt
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	2.95	1	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
diphenyldiselenide diphenyldiselenide: structure given in first source	2.17	1
benzeneseleninic acid benzeneseleninic acid: structure given in first source	2.17	1
sodium nitrate sodium nitrate : The inorganic nitrate salt of sodium.	4.28	17	inorganic nitrate salt; inorganic sodium salt	fertilizer; NMR chemical shift reference compound
sodium pyrophosphate sodium pyrophosphate: RN refers to diphosphoric acid, tetra-Na salt; structure. sodium diphosphate : An inorganic sodium salt comprised of a diphosphate(4-) anion and four sodium(1+) cations. More commonly known as tetrasodium pyrophosphate, it finds much use in the food industry as an emulsifier and in dental hygiene as a calcium-chelating salt.	4.38	19	inorganic sodium salt	chelator; food emulsifier; food thickening agent
sodium sulfate [no description available]	4.28	17	inorganic sodium salt
sodium selenite disodium selenite : An inorganic sodium salt composed of sodium and selenite ions in a 2:1 ratio.	2.01	1	inorganic sodium salt; selenite salt	nutraceutical
sodium bisulfide sodium bisulfide: RN given refers to sodium sulfide (Na(SH)); see also record for sodium sulfide (Na2S)	4.28	17
sodium azide Sodium Azide: A cytochrome oxidase inhibitor which is a nitridizing agent and an inhibitor of terminal oxidation. (From Merck Index, 12th ed). sodium azide : The sodium salt of hydrogen azide (hydrazoic acid).	4.28	17	inorganic sodium salt	antibacterial agent; explosive; mitochondrial respiratory-chain inhibitor; mutagen
sodium persulfate sodium persulfate: RN given refers to peroxydisulfuric acid, di-Na salt	4.38	19
2,2'-dipyridyl disulfide aldrithiol : A member of the class of pyridines that is pyridine which is substituted by a pyridin-2-yldisulfanediyl group at position 2. It is a reagent used in molecular biology as an oxidizing agent. Also used in peptide synthesis and for detecting thiols.. 2,2'-dipyridyl disulfide: disulfide is an important moiety in this cpd	2.17	1	organic disulfide; pyridines	oxidising agent
glutathione disulfide Glutathione Disulfide: A GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.	2.17	1	glutathione derivative; organic disulfide	Escherichia coli metabolite; mouse metabolite
benzeneboronic acid [no description available]	4.23	16	boronic acids
sulfamide sulfamide : The simplest of the sulfamic acids consisting of a single sulfur atom covalently bound by single bonds to two amino groups and by double bonds to two oxygen atoms.	4.23	16	sulfamides
selenomethionine [no description available]	2.01	1	amino acid zwitterion; selenomethionine	plant metabolite
selenomethylselenocysteine Se-methylselenocysteine : An alpha-amino acid compound having methylselanylmethyl as the side-chain.. Se-methyl-L-selenocysteine : An L-alpha-amino acid compound having methylselanylmethyl as the side-chain.	2.01	1	amino acid zwitterion; L-selenocysteine derivative; non-proteinogenic L-alpha-amino acid; Se-methylselenocysteine	antineoplastic agent
sodium bromide sodium bromide: RN given refers to parent cpd. sodium bromide : An inorganic sodium salt having bromide as the counterion.	4.28	17	bromide salt; inorganic sodium salt
arachidonic acid icosa-5,8,11,14-tetraenoic acid : Any icosatetraenoic acid with the double bonds at positions 5, 8, 11 and 14.. arachidonate : A long-chain fatty acid anion resulting from the removal of a proton from the carboxy group of arachidonic acid.	2.95	1	icosa-5,8,11,14-tetraenoic acid; long-chain fatty acid; omega-6 fatty acid	Daphnia galeata metabolite; EC 3.1.1.1 (carboxylesterase) inhibitor; human metabolite; mouse metabolite
retinol vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.	2.95	1	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
docosahexaenoate docosahexaenoic acid : Any C22 polyunsaturated fatty acid containing six double bonds.. docosahexaenoate : A polyunsaturated fatty acid anion that is the conjugate base of docosahexaenoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.. all-cis-docosa-4,7,10,13,16,19-hexaenoic acid : A docosahexaenoic acid having six cis-double bonds at positions 4, 7, 10, 13, 16 and 19.. efalex: a mixture of fish oil and primrose oil; used as a high-docosahexaenoic acid fatty acid supplement	2.95	1	docosahexaenoic acid; omega-3 fatty acid	algal metabolite; antineoplastic agent; Daphnia tenebrosa metabolite; human metabolite; mouse metabolite; nutraceutical
eicosapentaenoic acid icosapentaenoic acid : Any straight-chain, C20 polyunsaturated fatty acid having five C=C double bonds.. all-cis-5,8,11,14,17-icosapentaenoic acid : An icosapentaenoic acid having five cis-double bonds at positions 5, 8, 11, 14 and 17.	2.95	1	icosapentaenoic acid; omega-3 fatty acid	anticholesteremic drug; antidepressant; antineoplastic agent; Daphnia galeata metabolite; fungal metabolite; micronutrient; mouse metabolite; nutraceutical
sodium thiocyanate sodium thiocyanate: RN given refers to thiocyanic acid, Na salt. sodium thiocyanate : An organic sodium salt which is the monosodium salt of thiocyanic acid.	3.79	10	organic sodium salt
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	4.28	17	one-carbon compound; organic sodium salt	antacid; food anticaking agent
sodium cyanate sodium cyanate: used in treatment of sickle cell anemia; RN given refers to cyanic acid, Na salt	3.79	10	cyanate salt; one-carbon compound
sodium perchlorate sodium perchlorate : An inorganic sodium salt comprising equal numbers of sodium and perchlorate ions.	4.28	17	inorganic sodium salt
ditiocarb sodium [no description available]	4.44	20	organic molecular entity
sodium hexafluorophosphate sodium hexafluorophosphate : An inorganic sodium salt having hexafluorophosphate(1-) as the counterion. It is an electrolyte used in sodium-ion batteries.	3.03	4	inorganic sodium salt
linoleic acid Linoleic Acid: A doubly unsaturated fatty acid, occurring widely in plant glycosides. It is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (From Stedman, 26th ed). linoleic acid : An octadecadienoic acid in which the two double bonds are at positions 9 and 12 and have Z (cis) stereochemistry.	2.95	1	octadecadienoic acid; omega-6 fatty acid	algal metabolite; Daphnia galeata metabolite; plant metabolite
beta carotene beta Carotene: A carotenoid that is a precursor of VITAMIN A. Beta carotene is administered to reduce the severity of photosensitivity reactions in patients with erythropoietic protoporphyria (PORPHYRIA, ERYTHROPOIETIC).. provitamin A : A provitamin that can be converted into vitamin A by enzymes from animal tissues.	2.95	1	carotenoid beta-end derivative; cyclic carotene	antioxidant; biological pigment; cofactor; ferroptosis inhibitor; human metabolite; mouse metabolite; plant metabolite; provitamin A
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	2.95	1	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
azodicarbonamide [no description available]	2.17	1	organic molecular entity
selenocysteine Selenocysteine: A naturally occurring amino acid in both eukaryotic and prokaryotic organisms. It is found in tRNAs and in the catalytic site of some enzymes. The genes for glutathione peroxidase and formate dehydrogenase contain the TGA codon, which codes for this amino acid.. selenocysteine : An alpha-amino acid that consists of alanine where one of the methyl hydrogens is substituted with a seleno group.	2.01	1
sodium bisulfate [no description available]	3.32	6
sodium [no description available]	3.48	7
sodium bisulfite sodium hydrogensulfite : An inorganic sodium salt having hydrogensulfite as the counterion.. sodium bisulfite: has been used externally for parasitic skin diseases and as gastrointestinal antiseptic; structure	4.23	16	inorganic sodium salt; sulfite salt	allergen; food antioxidant; food colour retention agent; mutagen; reducing agent
sodium nitrite sodium nitrite : An inorganic sodium salt having nitrite as the counterion. Used as a food preservative and antidote to cyanide poisoning.. Sodium Nitrite: Nitrous acid sodium salt. Used in many industrial processes, in meat curing, coloring, and preserving, and as a reagent in ANALYTICAL CHEMISTRY TECHNIQUES. It is used therapeutically as an antidote in cyanide poisoning. The compound is toxic and mutagenic and will react in vivo with secondary or tertiary amines thereby producing highly carcinogenic nitrosamines.	4.28	17	inorganic sodium salt; nitrite salt	antidote to cyanide poisoning; antihypertensive agent; antimicrobial food preservative; food antioxidant; poison
unc 0638 UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source	2.17	1	quinazolines
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	2.95	1	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
enadoline enadoline: kappa-opioid receptor agonist; RN given refers to cpd without isomeric designation; PD 129290 (CAM 570; CI 977) is the S,S(-)-enantiomer; PD 129289 (CAM 569) is the corresponding R,R(+)-enantiomer	2.01	1
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(+-)-isomer [no description available]	3.23	1
u-50488 U50488 : A monocarboxylic acid amide obtained by formal condensation between the carboxy group of 3,4-dichlorophenylacetic acid and the secondary amino group of (1R,2R)-N-methyl-2-(pyrrolidin-1-yl)cyclohexanamine. 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer: A non-peptide, kappa-opioid receptor agonist which has also been found to stimulate the release of adrenocorticotropin (ADRENOCORTICOTROPIC HORMONE) via the release of hypothalamic arginine vasopressin (ARGININE VASOPRESSIN) and CORTICOTROPIN-RELEASING HORMONE. (From J Pharmacol Exp Ther 1997;280(1):416-21)	3.41	7	dichlorobenzene; monocarboxylic acid amide; N-alkylpyrrolidine	analgesic; antitussive; calcium channel blocker; diuretic; kappa-opioid receptor agonist
hydrocodone hydrocodone : A morphinane-like compound that is a semi-synthetic opioid synthesized from codeine.. Hydrocodone: Narcotic analgesic related to CODEINE, but more potent and more addicting by weight. It is used also as cough suppressant.	2.07	1	morphinane-like compound; organic heteropentacyclic compound	antitussive; mu-opioid receptor agonist; opioid analgesic
naloxone naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.. Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.	2.45	2	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	4.22	5	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	2.03	1	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	3.53	8	morphinane alkaloid
cyclorphan cyclorphan: was heading 1965-94 (see under MORPHINANS 1965-90); use MORPHINANS to search CYCLORPHAN 1966-94	3.89	12
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	2.03	1	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	2.46	2	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
enkephalin, ala(2)-mephe(4)-gly(5)- [no description available]	3.29	6	peptide
14-methoxymetopon 14-methoxymetopon: structure given in first source; has high affinity for the naloxone binding sites in rat brain	3.23	1
n-(cyclobutylmethyl)-8 beta-methyl-6-methylenemorphinan-3-ol N-(cyclobutylmethyl)-8 beta-methyl-6-methylenemorphinan-3-ol: has potent mixed agonist-antagonist narcotic properties; structure in first source	1.97	1
3,4-dichloro-n-methyl-n-(2-(1-pyrrolidinyl)cyclohexyl)-benzeneacetamide, (trans)-(-)-isomer [no description available]	2.45	2	acetamides
morphinans Morphinans: Compounds based on a partially saturated iminoethanophenanthrene, which can be described as ethylimino-bridged benzo-decahydronaphthalenes. They include some of the OPIOIDS found in PAPAVER that are used as ANALGESICS.	3.3	6	isoquinoline alkaloid fundamental parent; morphinane alkaloid
guanosine 5'-o-(3-thiotriphosphate) Guanosine 5'-O-(3-Thiotriphosphate): Guanosine 5'-(trihydrogen diphosphate), monoanhydride with phosphorothioic acid. A stable GTP analog which enjoys a variety of physiological actions such as stimulation of guanine nucleotide-binding proteins, phosphoinositide hydrolysis, cyclic AMP accumulation, and activation of specific proto-oncogenes.	2.03	1	nucleoside triphosphate analogue

Condition	Relationship Strength	Studies
Bacterial Infections, Gram-Negative [description not available]	2.07	1
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	2.07	1
American Trypanosomiasis [description not available]	2.08	1
Chagas Disease Infection with the protozoan parasite TRYPANOSOMA CRUZI, a form of TRYPANOSOMIASIS endemic in Central and South America. It is named after the Brazilian physician Carlos Chagas, who discovered the parasite. Infection by the parasite (positive serologic result only) is distinguished from the clinical manifestations that develop years later, such as destruction of PARASYMPATHETIC GANGLIA; CHAGAS CARDIOMYOPATHY; and dysfunction of the ESOPHAGUS or COLON.	2.08	1
Ache [description not available]	3.36	2
Pain An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.	3.36	2
Cocaine Abuse [description not available]	2	1
Cocaine-Related Disorders Disorders related or resulting from use of cocaine.	2	1

sodium selenate

Description

Cross-References

Synonyms (54)

Research Excerpts

Toxicity

Occurs in Manufacturing (9 Items)

Roles (3)

Drug Classes (1)

Protein Targets (24)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (93)

Molecular Functions (30)

Ceullar Components (44)

Bioassays (208)

Research

Studies (45)

Market Indicators

Research Demand Index: 55.59

Study Types

sodium selenate

Description

Cross-References

Synonyms (54)

Research Excerpts

Toxicity

Occurs in Manufacturing (9 Items)

Roles (3)

Drug Classes (1)

Protein Targets (24)

Inhibition Measurements

Activation Measurements

Other Measurements

Biological Processes (93)

Molecular Functions (30)

Ceullar Components (44)

Bioassays (208)

Research

Studies (45)

Market Indicators

Research Demand Index: 55.59

Study Types

Related Drugs (72)

Related Conditions (8)